Weekly Investment Analysts’ Ratings Updates for Insmed (INSM)

Several brokerages have updated their recommendations and price targets on shares of Insmed (NASDAQ: INSM) in the last few weeks:

• 1/30/2026 – Insmed had its price target raised by analysts at Morgan Stanley from $157.00 to $162.00. They now have an “equal weight” rating on the stock.
• 1/27/2026 – Insmed is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $231.00 price target on the stock.
• 1/27/2026 – Insmed is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $231.00 price target on the stock.
• 1/23/2026 – Insmed was upgraded by analysts at Roth Mkm to a “strong-buy” rating.
• 1/22/2026 – Insmed is now covered by analysts at Roth Mkm. They set a “buy” rating and a $212.00 price target on the stock.
• 1/22/2026 – Insmed had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/21/2026 – Insmed had its price target raised by analysts at Royal Bank Of Canada from $197.00 to $200.00. They now have an “outperform” rating on the stock.
• 1/12/2026 – Insmed was given a new $205.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – Insmed was given a new $157.00 price target on by analysts at Morgan Stanley.
• 1/6/2026 – Insmed had its price target lowered by analysts at UBS Group AG from $223.00 to $215.00. They now have a “buy” rating on the stock.
• 12/19/2025 – Insmed is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $202.00 price target on the stock.
• 12/18/2025 – Insmed had its price target lowered by analysts at HC Wainwright from $240.00 to $230.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Insmed was given a new $241.00 price target on by analysts at TD Cowen.
• 12/18/2025 – Insmed was given a new $212.00 price target on by analysts at Mizuho.
• 12/18/2025 – Insmed was given a new $203.00 price target on by analysts at Wedbush.
• 12/18/2025 – Insmed had its price target lowered by analysts at Royal Bank Of Canada from $215.00 to $195.00. They now have an “outperform” rating on the stock.
• 12/18/2025 – Insmed was given a new $195.00 price target on by analysts at Wells Fargo & Company.
• 12/18/2025 – Insmed had its “outperform” rating reaffirmed by analysts at Leerink Partners.
• 12/18/2025 – Insmed had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/18/2025 – Insmed was given a new $167.00 price target on by analysts at Wolfe Research. They now have an “outperform” rating on the stock.
• 12/18/2025 – Insmed was upgraded by analysts at Truist Financial Corporation to a “strong-buy” rating.
• 12/18/2025 – Insmed had its price target lowered by analysts at TD Cowen from $269.00 to $241.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Insmed had its price target lowered by analysts at Guggenheim from $230.00 to $221.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Insmed had its price target raised by analysts at Wells Fargo & Company from $217.00 to $234.00. They now have an “overweight” rating on the stock.
• 12/16/2025 – Insmed had its price target raised by analysts at Cantor Fitzgerald from $216.00 to $230.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $225.00 to $258.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Insmed had its price target raised by analysts at TD Cowen from $231.00 to $269.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Insmed was given a new $269.00 price target on by analysts at Jefferies Financial Group Inc..
• 12/10/2025 – Insmed had its “buy” rating reaffirmed by analysts at TD Cowen.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 1,447 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total transaction of $252,023.99. Following the completion of the sale, the chief financial officer owned 80,506 shares in the company, valued at approximately $14,021,730.02. The trade was a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07. Following the transaction, the chief executive officer owned 306,891 shares of the company’s stock, valued at $48,774,186.63. This represents a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 269,669 shares of company stock worth $49,310,335. 3.00% of the stock is owned by company insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.